Policy & Regulation
Feinstein Institutes Reveals Outcomes for COVID-19 Acute Kidney Injury Hospitalized Patients
25 September 2020 - - Research from the US-based Feinstein Institutes for Medical Research and Northwell Health's Division of Nephrology have previously reported that more than one third of the coronavirus disease 2019 (COVID-19) patients who sought treatment at the hospitals of Northwell Health, New York State's largest integrated health system, developed acute kidney injury, the organisations said.

New research from the largest study of its kind details a more comprehensive look at outcomes for COVID-19 patients with AKI, including kidney recovery, the need for dialytic support and post-discharge care.

AKI is a sudden episode of kidney injury or damage, preventing waste from being filtered within the body and can often lead to death.

The outcomes data published in the American Journal of Kidney Disease is a retrospective analysis of electronic health records of 9,657 hospitalized COVID-19 patients between March 1 and April 27, 2020.

The study found that 39.9% (3,854 of 9,657 of patients) developed AKI. While 83.4% (3,216) of those patients did not need kidney replacement therapies, 51.7% (1,663/3,216) survived.

Importantly, the majority of these patients 74.1% saw recovery of kidney function at the time of discharge.

Of patients with AKI who required KRT and survived, 66.7% (72/108) recovered kidney function. In the remaining AKI-KRT patients, a third (36/108) did not have kidney recovery, of which 91.7% who had not previously needed dialysis left the hospitals needing ongoing dialysis care after COVID-19 and AKI.

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.

We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine a new field of science that has the potential to revolutionise medicine.


Related Headlines